Flurbiprofen (DB00712): A Comprehensive Pharmacological and Clinical Monograph

I. Introduction and Drug Profile

1.1. Overview and Classification

Flurbiprofen is a potent small molecule drug classified as a nonsteroidal anti-inflammatory drug (NSAID).[1] It is a member of the phenylalkanoic acid derivative family and, more specifically, a propionic acid derivative. This classification places it in the same chemical and pharmacological class as other widely used NSAIDs such as ibuprofen, naproxen, and ketoprofen.[1] As a member of this class, Flurbiprofen exhibits a triad of core therapeutic actions: anti-inflammatory, analgesic (non-narcotic), and antipyretic properties, making it a versatile agent for the management of a spectrum of conditions characterized by pain and inflammation.[1]

The drug's development traces back to the highly productive research period of the 1960s at the research arm of Boots UK, which also yielded the discovery of several other foundational NSAIDs, including ibuprofen.[2] Flurbiprofen was patented in 1964 and, following extensive clinical development, received its initial approval for medical use in 1987, with approval in the United States by the Food and Drug Administration (FDA) following in 1988.[2] This historical context establishes Flurbiprofen as one of the classic, well-characterized NSAIDs that form the bedrock of anti-inflammatory pharmacotherapy. It is available in diverse formulations, including oral tablets for systemic conditions, ophthalmic solutions for ocular surgery, and oromucosal preparations for localized throat pain, reflecting its broad clinical utility.[1]

1.2. Chemical Identity and Physicochemical Properties

A thorough understanding of Flurbiprofen's chemical and physical characteristics is fundamental to appreciating its formulation, pharmacokinetic behavior, and interaction with biological systems.

Nomenclature and Structure

The generic name for the compound is Flurbiprofen, with several international nonproprietary names (INN) in use, including Flurbiprofène, Flurbiprofeno, and Flurbiprofenum.1 Its systematic IUPAC name is (RS)-2-(2-fluorobiphenyl-4-yl)propanoic acid, though it is also identified by synonyms such as (±)-2-fluoro-α-methyl-4-biphenylacetic acid.1 Structurally, Flurbiprofen is a monocarboxylic acid. Its molecular architecture consists of a 2-fluoro-[1,1'-biphenyl-4-yl] moiety that is linked to the second carbon (C-2) position of a propionic acid backbone.4 The chemical formula for Flurbiprofen is

C15​H13​FO2​, corresponding to a molecular weight of 244.26 g/mol.[2] A critical structural feature is its chirality; the molecule possesses a stereocenter at the alpha-carbon of the propionic acid group, and it is commercially produced and administered as a racemic mixture of its two enantiomers: (+)S-flurbiprofen and (-)R-flurbiprofen.[1]

Physical and Chemical Characteristics

Flurbiprofen presents as a white or slightly yellow crystalline solid.4 Its melting point is reported in the range of 110–117 °C.2 The compound exhibits slight solubility in water at physiological pH but is readily soluble in most polar organic solvents.4 Its lipophilicity, a key determinant of membrane permeability and distribution, is relatively high, with a reported partition coefficient (LogP) of approximately 4.16.4 This characteristic facilitates its absorption and binding to plasma proteins. As a carboxylic acid, it has an acidic pKa of approximately 4.03 to 4.3, indicating it exists predominantly in its ionized form at physiological pH.4

The seemingly minor structural difference between Flurbiprofen and its well-known relative, ibuprofen, is the substitution of a fluorine atom onto the biphenyl ring system.[11] This single atomic substitution is a key determinant of Flurbiprofen's distinct pharmacological profile. The high electronegativity and specific placement of the fluorine atom are understood to enhance the molecule's binding affinity within the active site of the cyclooxygenase (COX) enzyme.[12] This enhanced interaction directly translates into greater inhibitory power, making Flurbiprofen one of the most potent NSAIDs available in terms of its ability to block prostaglandin synthesis.[1]

This high potency, however, creates a critical clinical trade-off. While it allows for effective anti-inflammatory action at lower milligram doses compared to many other NSAIDs, its potent and non-selective inhibition of both COX-1 and COX-2 enzymes means that the significant risk of gastrointestinal toxicity, which is primarily mediated by COX-1 inhibition, is fully preserved. Therefore, the drug's potency does not confer an improved safety profile; it simply shifts the dose-response curve for both efficacy and toxicity. Furthermore, the drug's existence as a racemic mixture adds another layer of pharmacological complexity. The S-enantiomer is primarily responsible for the anti-inflammatory effects mediated by COX inhibition, while the R-enantiomer, which undergoes minimal conversion to the S-form in humans, possesses distinct biological activities that are independent of the COX pathway.[1] This dual nature suggests that Flurbiprofen is not merely a "stronger ibuprofen" but a unique pharmacological agent whose full spectrum of effects is still being elucidated. This complexity challenges a simplistic view of the drug and points toward future research avenues, such as the development of enantiopure formulations to harness specific therapeutic actions while potentially mitigating others.

Property	Value	Source(s)
DrugBank ID	DB00712	1
CAS Number	5104-49-4	2
Type	Small Molecule	1
IUPAC Name	(RS)-2-(2-fluorobiphenyl-4-yl)propanoic acid	2
Chemical Formula	C15​H13​FO2​	2
Molar Mass	244.26 g/mol	2
Physical Description	White to slightly yellow crystalline solid	4
Melting Point	110–117 °C	2
Water Solubility	8 mg/L (at 22 °C)	4
LogP	4.16	4
pKa (acidic)	4.03–4.3	4

II. Pharmacology and Molecular Action

2.1. Primary Mechanism: Non-Selective Cyclooxygenase (COX) Inhibition

The principal mechanism of action for Flurbiprofen, consistent with its classification as a classic NSAID, is the reversible and non-selective inhibition of the cyclooxygenase (COX) enzymes.[1] These enzymes, which exist as two primary isoforms, Prostaglandin G/H synthase 1 (COX-1) and Prostaglandin G/H synthase 2 (COX-2), are the rate-limiting step in the biosynthesis of prostaglandins from their precursor, arachidonic acid.[1] By competitively binding to the active site of these enzymes, Flurbiprofen sterically blocks the access of arachidonic acid, thereby preventing its conversion into the unstable prostaglandin endoperoxide intermediates, prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2).[1] This blockade leads to a profound decrease in the synthesis and release of various downstream prostaglandins, which are potent lipid mediators responsible for orchestrating the cardinal signs of inflammation (pain, swelling, redness, heat) and fever.[15]

The dual inhibition of both COX isoforms is central to both the therapeutic efficacy and the adverse effect profile of Flurbiprofen. The inhibition of COX-2, an enzyme isoform that is typically absent in most tissues but is rapidly induced at sites of injury or inflammation by cytokines and other inflammatory stimuli, is primarily responsible for the drug's desired anti-inflammatory and analgesic effects.[15] By suppressing COX-2 activity, Flurbiprofen reduces the production of pro-inflammatory prostaglandins that sensitize nociceptors and increase vascular permeability. In contrast, the inhibition of COX-1, which is constitutively expressed in many tissues and performs vital homeostatic or "housekeeping" functions, is the primary driver of the most common and serious NSAID-related toxicities.[15] In the gastrointestinal tract, COX-1-derived prostaglandins are crucial for maintaining mucosal integrity and blood flow; their inhibition compromises these protective mechanisms, leading to an increased risk of dyspepsia, ulceration, and life-threatening bleeding.

Flurbiprofen is recognized as a highly potent inhibitor of the COX enzymes. In vitro studies have reported 50% inhibitory concentration (IC50​) values of 0.1 µM for human COX-1 and 0.4 µM for human COX-2, while other analyses have found values of 0.04 µM for COX-1 and 0.51 µM for COX-2.[20] These data consistently demonstrate high potency and a slight selectivity toward the COX-1 isoform. This pharmacological profile—high potency combined with non-selectivity—is the central paradox of Flurbiprofen. It explains why, despite its proven efficacy, it has not supplanted less potent but potentially better-tolerated agents like ibuprofen in over-the-counter settings. The drug's potency is a clear advantage for managing severe inflammatory conditions, such as rheumatoid arthritis, where robust anti-inflammatory action is paramount. However, the potent inhibition of COX-1 means that the risk of serious gastrointestinal harm is not merely present but potentially pronounced. This positions Flurbiprofen as a "heavy-hitter" prescription NSAID, a powerful therapeutic tool whose use is reserved for clinical scenarios where its substantial efficacy is judged to outweigh its inherent and significant risks, a decision that necessitates careful patient evaluation and stratification.

2.2. The Role of Stereochemistry: S- and R-Enantiomers

Flurbiprofen is administered clinically as a racemic mixture, containing equal parts of its two stereoisomers: (+)S-flurbiprofen and (-)R-flurbiprofen.[1] This chirality is of significant pharmacological importance, as the two enantiomers possess distinct biological activities. The (+)S-enantiomer is widely considered the "active" form in the traditional sense, as it is responsible for the vast majority of the drug's anti-inflammatory activity through potent inhibition of the COX enzymes.[1] This stereospecificity is a common feature among NSAIDs of the propionic acid class.

A crucial pharmacokinetic distinction between Flurbiprofen and some other profens, such as ibuprofen, is the metabolic fate of the R-enantiomer. In humans, the metabolic conversion (chiral inversion) of R-flurbiprofen to the COX-inhibiting S-flurbiprofen is minimal.[9] This lack of inversion means that the R-enantiomer persists in the body at significant concentrations and for a prolonged duration, allowing it to exert its own unique biological effects independent of the S-form. While the S-enantiomer drives inflammation control, evidence suggests that both enantiomers may contribute to the overall analgesic effect of the drug, hinting at the involvement of non-prostaglandin-mediated pathways in pain relief.[1]

2.3. Secondary and Investigational Mechanisms

Beyond its primary action on COX enzymes, research has uncovered additional mechanisms that contribute to the pharmacological profile of Flurbiprofen, particularly its R-enantiomer.

R-Flurbiprofen and MRP4 Inhibition

A novel and significant non-COX-mediated mechanism has been identified for (-)R-flurbiprofen. This enantiomer has been shown to inhibit the multidrug resistance–associated protein 4 (MRP4), also known by its gene name, ABCC4.1 MRP4 is an ATP-binding cassette transporter that functions as a key cellular efflux pump for prostaglandins, actively transporting them from the intracellular space to the extracellular environment where they can act on cell surface receptors.14 By inhibiting MRP4, R-flurbiprofen effectively traps newly synthesized prostaglandins, such as prostaglandin E2 (PGE2), inside the cell. This action reduces the extracellular concentration of these inflammatory mediators and curtails the inflammatory signaling cascade without directly blocking the COX enzymes responsible for their synthesis. This mechanism represents an alternative pathway to achieving an anti-inflammatory effect and may be particularly relevant in tissues or disease states, such as certain cancers, that have high levels of MRP4 expression.14

Other Potential Actions

In vitro and in vivo studies have suggested other biological activities for Flurbiprofen. It has been shown to inhibit the growth of tumor cells and to regulate the expression of prostate stem cell antigen via the activation of the Akt kinase pathway.20 Additionally, it can inhibit the proliferation of fibroblasts in vitro.20 There is also evidence to suggest that Flurbiprofen may modulate neuronal pathways involved in pain transmission by directly affecting the activity of ion channels and the release of neurotransmitters, which could contribute to its analgesic effects beyond prostaglandin inhibition.15 Furthermore, early research has explored its potential role in Alzheimer's disease, where it and its enantiomers have been shown to selectively lower levels of the amyloid-beta 42 peptide (Aβ42) by directly targeting and modulating the activity of the γ-secretase enzyme complex.23 These diverse and emerging mechanisms indicate that the biological effects of Flurbiprofen are more complex than can be explained by COX inhibition alone.

III. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical efficacy and safety of Flurbiprofen are governed by its pharmacokinetic profile, which describes its movement into, through, and out of the body. The processes of absorption, distribution, metabolism, and excretion (ADME) determine the onset, intensity, and duration of the drug's action.

3.1. Absorption

Following oral administration in tablet form, Flurbiprofen is absorbed rapidly and almost completely from the gastrointestinal tract.[1] The mean oral bioavailability is high, estimated at 96% when compared to an oral solution, indicating efficient absorption.[9] Peak plasma concentrations (Cmax) are typically achieved within 0.5 to 4 hours, with an average time to peak (Tmax) of approximately 2 hours.[1] The presence of food or the co-administration of antacids may slow the rate of absorption, thereby delaying the time to reach peak concentration, but these factors do not significantly alter the total amount of drug absorbed (i.e., the area under the curve, or AUC).[9] This is an important clinical consideration, as it allows patients to take Flurbiprofen with food to minimize local gastric irritation without compromising the overall therapeutic effect.

3.2. Distribution

Once absorbed into the systemic circulation, Flurbiprofen exhibits a low apparent volume of distribution (Vd), approximately 0.12 L/kg.[1] This low Vd suggests that the drug is largely confined to the plasma and extracellular fluids and does not extensively partition into deep tissue compartments.

A defining pharmacokinetic characteristic of Flurbiprofen is its exceptionally high degree of binding to plasma proteins, exceeding 99%.[1] It binds primarily to albumin. This extensive protein binding has several important consequences. It limits the amount of free, pharmacologically active drug available to interact with target tissues, and it creates a potential for clinically significant drug-drug interactions. Drugs that are also highly protein-bound can compete for the same binding sites on albumin, potentially displacing Flurbiprofen and increasing its free concentration, or vice versa. This can lead to an unpredictable increase in pharmacological effect or toxicity.

Regarding distribution into specific compartments, Flurbiprofen is poorly excreted into human breast milk. Studies have estimated that a fully breastfed infant would receive a very low dose, ranging from 0.1% to 0.5% of the maternal weight-adjusted dosage.[1] Based on these low levels and the drug's short half-life, adverse effects in a breastfed infant are considered unlikely, particularly if the infant is older than two months.[25]

3.3. Metabolism and the Central Role of CYP2C9

The primary route of Flurbiprofen elimination is through extensive hepatic metabolism, which accounts for more than 90% of the drug's total clearance.[2] The biotransformation is mediated predominantly by the Cytochrome P450 (CYP) superfamily of enzymes. Specifically, the CYP2C9 isoenzyme plays the principal role in the metabolism of Flurbiprofen, catalyzing its hydroxylation to form the major metabolite, 4'-hydroxy-flurbiprofen.[1] This metabolite has been shown to possess little to no anti-inflammatory activity, making this metabolic step a true detoxification and inactivation pathway.[1] Several other minor metabolites, including 3',4'-dihydroxy-flurbiprofen and 3'-hydroxy-4'-methoxy-flurbiprofen, have also been identified in human plasma and urine.[9]

Pharmacogenomics of CYP2C9

The heavy reliance on a single metabolic pathway makes Flurbiprofen's pharmacokinetics susceptible to genetic variation. The gene encoding the CYP2C9 enzyme is highly polymorphic in the human population, with several common variants (alleles), most notably CYP2C92 and CYP2C93, that result in enzymes with significantly reduced catalytic activity.26 Individuals who inherit one or two of these reduced-function alleles are classified as "intermediate" or "poor" metabolizers, respectively. In these individuals, the metabolic clearance of Flurbiprofen is markedly decreased, which can lead to abnormally high plasma concentrations of the drug following standard doses.9 This elevated exposure significantly increases the risk of dose-dependent adverse effects, such as gastrointestinal bleeding and renal toxicity.

This strong and predictable gene-drug interaction has matured into actionable clinical guidance. The FDA-approved drug label for Flurbiprofen and guidelines from organizations like the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend caution and dose adjustments for patients who are known or suspected to be CYP2C9 poor metabolizers.[22] For these patients, initiating therapy with 25–50% of the lowest recommended starting dose is advised to avoid excessive drug accumulation and mitigate the risk of adverse events.[22] This makes Flurbiprofen a key example of the application of personalized medicine within the NSAID class. Knowledge of a patient's genetic makeup can directly inform prescribing decisions, shifting the paradigm from a reactive approach of managing side effects to a proactive, preventative strategy based on an individual's predicted metabolic capacity.

3.4. Excretion

Following hepatic metabolism, Flurbiprofen and its metabolites are eliminated from the body primarily via the kidneys.[2] Approximately 70% of an administered dose is recovered in the urine, predominantly as the parent drug and its various metabolites, many of which are in their conjugated (acyl-glucuronide) forms.[1] Renal elimination of the unchanged parent drug is a minor pathway, with less than 3% of the dose being excreted in this form.[1] This underscores the critical importance of hepatic biotransformation prior to renal clearance.

The mean terminal elimination half-life (t1/2​) of Flurbiprofen is relatively short, reported to be between 4.7 and 5.7 hours.[2] This pharmacokinetic property supports a multiple-dose-per-day regimen (e.g., two to four times daily) to maintain steady-state therapeutic concentrations. Because renal elimination is the final step for the clearance of its metabolites, dose adjustments may be necessary in patients with moderate to severe renal dysfunction to prevent their accumulation.[9]

Pharmacokinetic Parameter	Normal Healthy Adults*	Geriatric Arthritis Patients†	End Stage Renal Disease Patients*	Alcoholic Cirrhosis Patients‡	Source(s)
Peak Concentration (Cmax)	14 µg/mL	16 µg/mL	9 µg/mL	9 µg/mL	24
Time to Peak (Tmax)	1.9 h	2.2 h	2.3 h	1.2 h	24
Area Under the Curve (AUC)	83 µg∙h/mL	77 µg∙h/mL	44 µg∙h/mL	50 µg∙h/mL	24
Apparent Volume of Distribution (Vd)	14 L	12 L	10 L	14 L	24
Terminal Half-life (t1/2​)	7.5 h	5.8 h	3.3 h	5.4 h	24
*Data from a 100 mg single-dose study. †Data from a steady-state evaluation of 100 mg every 12 hours. ‡Data from a 200 mg single-dose study.

IV. Clinical Applications and Therapeutic Efficacy

Flurbiprofen's potent anti-inflammatory and analgesic properties have been harnessed in a variety of formulations, each tailored to specific clinical indications. The availability of systemic, ophthalmic, and oromucosal products allows for targeted therapy that maximizes efficacy while attempting to manage the drug's significant risk profile. This strategic use of different formulations represents a critical approach to risk mitigation, allowing the drug's potent local effects to be utilized in a manner that minimizes systemic exposure and its associated dangers. For instance, the development of low-dose local therapies like lozenges and eye drops was likely driven by the need to make Flurbiprofen's powerful anti-inflammatory action available for conditions where high-dose systemic therapy would be inappropriate and hazardous. This approach effectively separates the desired local benefits from the dangerous systemic risks, creating a more favorable risk-benefit profile for specific, localized conditions and dramatically expanding the drug's clinical utility.

4.1. Systemic Formulation (Oral Tablets)

Oral Flurbiprofen is the cornerstone of its systemic use, primarily for chronic inflammatory conditions and acute pain.

FDA-Approved Indications

The primary FDA-approved indications for Flurbiprofen tablets are for the acute or long-term symptomatic management of rheumatoid arthritis (RA) and osteoarthritis (OA).1 These chronic inflammatory joint diseases are characterized by pain, swelling, stiffness, and progressive joint damage, and NSAIDs like Flurbiprofen are a mainstay of symptomatic relief.

Efficacy in Arthritis

Numerous clinical trials have substantiated the efficacy of Flurbiprofen in these conditions. At typical daily doses of 200–300 mg, it has been shown to significantly reduce the signs and symptoms of RA and OA, leading to improvements in patient-reported pain, joint tenderness, swelling, and physical function.31 In comparative clinical studies, Flurbiprofen has demonstrated efficacy that is comparable to, and in some cases superior to, other potent NSAIDs, including therapeutic doses of aspirin, indomethacin, ibuprofen, and naproxen.13 A comprehensive meta-analysis of its use in rheumatoid arthritis concluded that Flurbiprofen is a valuable therapeutic alternative, particularly noting its favorable efficacy-to-tolerance ratio when compared with agents like aspirin and indomethacin.35

Off-Label and Other Systemic Uses

Beyond its primary approved indications, Flurbiprofen is widely used for a range of other conditions. These include the management of ankylosing spondylitis, another chronic inflammatory arthritis primarily affecting the spine.1 It is also effective for primary dysmenorrhea (menstrual pain), where its inhibition of uterine prostaglandin synthesis provides significant pain relief.1 Additionally, it is used for various forms of mild-to-moderate acute pain, especially when an inflammatory component is present, such as in cases of bursitis, tendonitis, soft tissue trauma, back pain, and sciatica.1 Its efficacy as a single-dose analgesic for acute postoperative pain, such as after dental surgery, has also been well established in controlled trials.37

4.2. Ophthalmic Formulation (Solution)

Indication and Mechanism

Flurbiprofen sodium is formulated as a 0.03% sterile ophthalmic solution, marketed under the brand name Ocufen and as a generic.2 Its sole FDA-approved indication is for the inhibition of intraoperative miosis (constriction of the pupil).1 During ocular surgery, particularly cataract extraction, surgical trauma can induce the release of prostaglandins in the anterior chamber of the eye. These prostaglandins act on the iris sphincter muscle, causing the pupil to constrict. By applying Flurbiprofen topically to the eye before surgery, prostaglandin synthesis is blocked locally, which helps to maintain pupillary dilation (mydriasis) and provides the surgeon with a better and more stable view of the operative field.39 It is also used off-label for the management of postoperative ocular inflammation and pain.8 The ophthalmic formulation is also used in veterinary medicine for treating inflammatory eye conditions like uveitis in dogs and cats.42

4.3. Oromucosal Formulations (Lozenges and Spray)

Indication and Efficacy

For localized relief of throat pain, Flurbiprofen is available as an 8.75 mg lozenge (e.g., Strefen, Strepsils Maxpro) and as an oromucosal spray.2 These over-the-counter or pharmacy-only products are indicated for the short-term symptomatic relief of sore throat (pharyngitis) in adults and adolescents over the age of 12.43 The local delivery of the drug to the inflamed pharyngeal tissues provides a direct anti-inflammatory and analgesic effect.

Multiple randomized, placebo-controlled clinical trials have confirmed the efficacy of this low-dose formulation. A single 8.75 mg dose has been shown to provide rapid onset of pain relief, often within 30 minutes, which is sustained for up to six hours.[46] Compared to placebo, Flurbiprofen lozenges and spray significantly reduce patient-reported sore throat pain intensity, difficulty swallowing (dysphagia), and the sensation of a swollen throat.[49] Importantly, this efficacy has also been demonstrated in a post hoc analysis of patients with laboratory-confirmed streptococcal pharyngitis who were concurrently receiving antibiotic therapy, indicating that Flurbiprofen provides symptomatic relief that is independent of, and complementary to, the antibacterial treatment.[52]

V. Dosage, Formulations, and Administration

The appropriate use of Flurbiprofen requires a clear understanding of its available formulations, strengths, and the specific dosing regimens recommended for each clinical indication. Adherence to these guidelines is crucial for maximizing therapeutic benefit while minimizing the risk of adverse events.

5.1. Systemic Administration (Oral Tablets)

• Available Strengths: Flurbiprofen oral tablets are manufactured in 50 mg and 100 mg strengths.[29]
• Dosing for Rheumatoid Arthritis and Osteoarthritis: For adult patients, the recommended total daily dosage is 200 mg to 300 mg. This total daily amount should be divided and administered two, three, or four times per day.[28] For example, a common regimen might be 100 mg taken twice daily or 50 mg taken four times daily. A clinical study in patients with rheumatoid arthritis found that a twice-daily schedule (100 mg BID) was equally as effective as a four-times-daily schedule (50 mg QID).[56]
• Maximum Dose: The largest recommended single dose should not exceed 100 mg, and the maximum total daily dose is 300 mg.[5]
• Administration Guidelines: To reduce the risk of gastrointestinal upset and irritation, it is strongly recommended that patients take the tablets with food, milk, or a full 8–12 ounce glass of water.[33]

5.2. Ophthalmic Administration (Solution)

• Available Strength: Flurbiprofen sodium is available as a 0.03% sterile ophthalmic solution, typically in a 2.5 mL dropper bottle.[58]
• Dosing for Inhibition of Intraoperative Miosis: The standard pre-surgical protocol involves the administration of a total of four drops into the eye undergoing surgery. One drop is instilled approximately every 30 minutes, beginning 2 hours before the scheduled surgery.[38]
• Administration Guidelines: Proper aseptic technique is essential. Patients and healthcare providers should wash their hands before administration and avoid touching the dropper tip to the eye or any other surface to prevent contamination.[58] If surgery is being performed on both eyes, a separate, new bottle of the solution should be used for each eye to prevent cross-contamination.[38]

5.3. Oromucosal Administration (Lozenges)

• Available Strength: Each lozenge contains a standard dose of 8.75 mg of Flurbiprofen.[46]
• Dosing for Symptomatic Relief of Sore Throat: This formulation is intended for adults and children aged 12 years and older. The recommended dosage is one lozenge to be sucked slowly in the mouth every 3 to 6 hours, as needed for symptom relief.[43]
• Maximum Dose and Duration of Use: It is critical not to exceed a maximum of 5 lozenges in any 24-hour period. The lozenges are intended for short-term use only, and treatment should not extend beyond three consecutive days unless specifically advised by a physician.[43]
• Administration Guidelines: To prevent localized mucosal irritation, users should move the lozenge around in their mouth as it dissolves rather than keeping it in one position.[43]

Formulation	Common Brand Name(s)	Strength(s)	Indication	Recommended Dosage	Maximum Dose / Duration
Oral Tablet	Ansaid, Froben	50 mg, 100 mg	Rheumatoid Arthritis, Osteoarthritis	200–300 mg/day, divided into 2–4 doses	Single dose: 100 mg; Daily: 300 mg
Ophthalmic Solution	Ocufen (generic available)	0.03%	Inhibition of Intraoperative Miosis	1 drop every 30 min, starting 2 hours pre-op (total 4 drops)	For pre-operative use only
Oromucosal Lozenge	Strepfen, Strepsils Intensive	8.75 mg	Short-term relief of sore throat	1 lozenge every 3–6 hours as needed	5 lozenges per 24 hours; Max 3 days use

VI. Comprehensive Safety and Tolerability Profile

The clinical use of Flurbiprofen is fundamentally guided by its safety profile. While an effective anti-inflammatory and analgesic agent, its potent, non-selective inhibition of prostaglandins results in a spectrum of predictable, on-target toxicities that affect multiple organ systems. The risks associated with Flurbiprofen are significant and necessitate a thorough understanding by clinicians and patients to ensure a favorable risk-benefit balance. The "side effects" are not random occurrences but are the direct, foreseeable consequences of the drug's core mechanism. Suppressing prostaglandins to alleviate joint inflammation simultaneously impairs their vital protective functions in the stomach, kidneys, and cardiovascular system. This reality demands a holistic patient assessment that extends beyond the primary complaint to consider the patient's baseline renal, cardiovascular, and gastrointestinal health, making the decision to prescribe a calculated risk assessment across the entire physiological system.

6.1. FDA Boxed Warnings: The Core Risks

In recognition of the most severe risks associated with its use, the U.S. FDA has mandated that the labeling for Flurbiprofen, like all systemic NSAIDs, include "black box" warnings. These are the agency's strongest level of caution and highlight two major categories of potentially fatal adverse events.[24]

Cardiovascular Thrombotic Events

Systemic Flurbiprofen use is associated with an increased risk of serious and potentially fatal cardiovascular thrombotic events, including myocardial infarction (MI) and stroke.32 This risk is not confined to long-term users; it can emerge as early as the first weeks of treatment and appears to increase with both the duration of use and the dosage administered. The risk is present in all patients, regardless of whether they have pre-existing cardiovascular disease or risk factors. However, patients with known cardiovascular disease or multiple risk factors (e.g., hypertension, diabetes, smoking) have a higher absolute incidence of these events due to their elevated baseline risk.67

Gastrointestinal Bleeding, Ulceration, and Perforation

Flurbiprofen causes an increased risk of serious and potentially fatal gastrointestinal (GI) adverse events. These include bleeding, the formation of peptic ulcers, and perforation of the stomach or intestines.1 A particularly dangerous aspect of this toxicity is that these events can occur at any point during therapy and often without any preceding warning symptoms. The risk is substantially higher in certain populations, most notably elderly patients and individuals with a prior history of peptic ulcer disease or GI bleeding.32

6.2. Contraindications

There are specific clinical situations and patient populations in which the use of Flurbiprofen is contraindicated due to an unacceptably high risk of severe harm.

• Hypersensitivity: It is contraindicated in patients with a known hypersensitivity to Flurbiprofen or any of the excipients in the formulation.[18]
• Aspirin/NSAID-Induced Asthma: It must not be used in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or another NSAID. These patients are at high risk for severe, potentially fatal anaphylactic reactions.[18]
• Coronary Artery Bypass Graft (CABG) Surgery: Flurbiprofen is strictly contraindicated for the treatment of peri-operative pain in the setting of CABG surgery. Clinical trials have shown an increased incidence of myocardial infarction and stroke when NSAIDs are used in this context.[18]
• Active Gastrointestinal Disease: It is contraindicated in patients with active peptic ulcers, active GI bleeding, or a history of recurrent peptic ulceration or GI hemorrhage.[69]
• Severe Organ Failure: Use is contraindicated in patients with severe heart failure, severe hepatic failure, or severe renal failure.[69]
• Late Pregnancy: Flurbiprofen is contraindicated during the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus and other potential fetal harms.[69]

6.3. Adverse Drug Reactions (ADRs)

Beyond the boxed warnings, Flurbiprofen is associated with a wide range of adverse effects across various organ systems.

• Gastrointestinal: These are the most frequently reported adverse effects. Common issues include dyspepsia (heartburn), abdominal pain, nausea, vomiting, diarrhea, and constipation.[1]
• Cardiovascular: In addition to thrombotic events, Flurbiprofen can cause fluid retention (edema) and may lead to the new onset of hypertension or the worsening of pre-existing hypertension.[5] These effects can precipitate or exacerbate heart failure.
• Renal: The drug can cause direct renal injury, including acute renal failure, interstitial nephritis, and renal papillary necrosis. It can also lead to hyperkalemia (high potassium levels).[1] The risk of renal toxicity is elevated in patients with pre-existing kidney disease, heart failure, liver dysfunction, dehydration, or those taking diuretics or ACE inhibitors.
• Hepatic: Asymptomatic elevations in liver enzymes (ALT, AST) are relatively common, occurring in up to 15% of patients on long-term therapy, though they are usually mild and transient.[5] Rare but serious cases of drug-induced liver injury, including cholestatic jaundice and fulminant hepatitis leading to acute liver failure, have been reported.[5]
• Dermatologic: Common skin reactions include rash and pruritus (itching).[1] Flurbiprofen can also cause rare but life-threatening severe skin reactions, such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).[68]
• Hematologic: Due to its antiplatelet effects, Flurbiprofen can prolong bleeding time. It can also cause anemia, which may be due to occult GI blood loss.[1]
• Neurologic: Common central nervous system effects include headache, dizziness, and drowsiness.[1]
• Special Senses: Tinnitus (ringing in the ears) and changes in vision have been reported.[1]

6.4. Drug and Substance Interactions

Flurbiprofen has numerous clinically significant interactions with other drugs and substances, which can potentiate its toxicity or alter the efficacy of concomitant medications. There are over 400 drugs known to interact with Flurbiprofen.[72]

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation
Anticoagulants (e.g., Warfarin)	Additive antiplatelet effect and direct gastric mucosal injury by Flurbiprofen.	Markedly increased risk of serious gastrointestinal and other bleeding.	Avoid combination if possible. If necessary, monitor closely for signs of bleeding (e.g., INR, CBC). 69
Antiplatelet Agents (e.g., Aspirin, Clopidogrel)	Additive inhibition of platelet aggregation.	Increased risk of bleeding, particularly GI bleeding.	Concomitant use increases risk. Use with caution and monitor for bleeding. Avoid using multiple NSAIDs. 69
Other NSAIDs (e.g., Ibuprofen, Naproxen)	Additive pharmacodynamic effects and toxicity.	Increased risk of GI, renal, and cardiovascular adverse events without additional therapeutic benefit.	Combination is not recommended and should be avoided. 45
ACE Inhibitors & ARBs (e.g., Lisinopril, Losartan)	Inhibition of renal vasodilatory prostaglandins, leading to reduced renal blood flow and sodium excretion.	Blunted antihypertensive effect; increased risk of acute renal failure, especially in elderly or volume-depleted patients.	Monitor blood pressure and renal function closely. Ensure adequate hydration. 24
Diuretics (Loop & Thiazide)	Inhibition of renal prostaglandin synthesis reduces the natriuretic (salt-excreting) effect of diuretics.	Reduced diuretic and antihypertensive efficacy; increased risk of renal toxicity.	Monitor blood pressure, electrolytes, and renal function. Patients may require higher diuretic doses. 24
Lithium	NSAIDs decrease the renal clearance of lithium.	Increased plasma lithium levels, leading to a high risk of lithium toxicity (e.g., tremor, confusion, seizures).	Avoid combination if possible. If used together, monitor lithium levels frequently and adjust lithium dose as needed. 24
Methotrexate	NSAIDs can decrease the renal clearance of methotrexate.	Increased plasma methotrexate levels, leading to a high risk of severe hematologic and GI toxicity.	Use with extreme caution, especially with high-dose methotrexate therapy. Monitor renal function and for signs of methotrexate toxicity. 24
SSRIs & SNRIs (e.g., Fluoxetine, Venlafaxine)	These antidepressants also have antiplatelet effects.	Additive effect on platelet function, increasing the risk of bleeding, particularly GI bleeding.	Use with caution. Monitor for signs and symptoms of bleeding. 18

Alcohol and Tobacco

The concomitant use of alcohol or tobacco with Flurbiprofen significantly increases the risk of gastrointestinal bleeding. Alcohol is a direct mucosal irritant, and both substances can exacerbate the damage caused by prostaglandin inhibition, creating a synergistic effect that elevates the risk of ulceration and hemorrhage.73 Patients should be strongly advised to avoid or limit alcohol consumption and to cease smoking while taking Flurbiprofen.

VII. Regulatory History and Commercial Overview

7.1. Development and Approval Timeline

The development of Flurbiprofen was part of a major wave of NSAID discovery in the mid-20th century.

• 1960s: The molecule was first synthesized and developed by the research division of Boots UK.[2]
• 1964: The compound was patented by Boots UK.[2]
• 1987: Flurbiprofen received its first approval for medical use.[2]
• 1988: The U.S. Food and Drug Administration (FDA) approved Flurbiprofen for use in the United States, with the initial approval for oral tablets.[2] The ophthalmic solution was approved under New Drug Application (NDA) 019404.[27]
• 1994: The first generic version of oral Flurbiprofen was approved in the US, increasing its accessibility.[2]

7.2. Significant Regulatory Updates

The regulatory landscape for Flurbiprofen, along with all NSAIDs, has evolved significantly as understanding of their risks has grown.

• 2005: Following a comprehensive review of cardiovascular safety data for the entire class, the FDA required sponsors of all prescription NSAIDs to revise their labeling to include a boxed warning highlighting the increased risk of cardiovascular thrombotic events.[67]
• 2020: The FDA mandated another significant label update for all NSAIDs. This communication warned of the risk of oligohydramnios (low amniotic fluid) due to rare but serious fetal kidney problems when NSAIDs are used during the second half of pregnancy. The agency now recommends avoiding NSAID use in pregnant women at 20 weeks of gestation or later.[2]

7.3. Brand Names and Manufacturers

Flurbiprofen is marketed globally under numerous brand names and by a wide range of pharmaceutical companies.

• Systemic (Oral Tablets): In the United States, the most recognized brand name is Ansaid, originally marketed by Pfizer.[2] International brand names include Froben, Cebutid, and Brufen.[2] Generic versions are produced by manufacturers such as Teva Pharmaceuticals and Mylan.[68]
• Ophthalmic Solution: The primary brand name has been Ocufen.[2] While the brand name product has been discontinued in some regions, generic flurbiprofen sodium 0.03% eye drops are widely available from various manufacturers.[41]
• Oromucosal Formulations: The lozenges and sprays are commonly marketed under the brand names Strepfen and Strepsils Intensive or Strepsils Maxpro, primarily by Reckitt Benckiser.[2]
• API Manufacturers: The active pharmaceutical ingredient (API) for Flurbiprofen is produced by numerous global manufacturers, including Vasudha Pharma Chem Ltd. and Suryakala Laboratories Pvt Ltd.[82]

VIII. Conclusion and Future Outlook

8.1. Summary of Risk-Benefit Profile

Flurbiprofen stands as a potent and effective nonsteroidal anti-inflammatory drug with a well-established role in the management of inflammatory arthritis, acute pain, and localized inflammatory conditions. Its clinical versatility is significantly enhanced by its availability in multiple formulations—systemic oral tablets, topical ophthalmic solution, and oromucosal lozenges and sprays—which allow for therapy to be tailored to the specific clinical need. The oral formulation provides powerful systemic relief for chronic diseases like rheumatoid and osteoarthritis, while the local formulations offer targeted action with minimized systemic exposure for conditions like sore throat and for use in ocular surgery.

This efficacy, however, is inextricably linked to a substantial and well-defined safety risk profile. The potent, non-selective inhibition of COX enzymes that drives its therapeutic effect also underlies its most serious toxicities. The FDA's black box warnings for severe cardiovascular thrombotic events and life-threatening gastrointestinal bleeding, ulceration, and perforation are a stark reminder of these inherent risks. Consequently, the appropriate clinical use of systemic Flurbiprofen is predicated on a careful and continuous risk-benefit assessment. Its utility is maximized through judicious patient selection, adherence to the principle of using the lowest effective dose for the shortest possible duration, and vigilant monitoring for adverse events.

8.2. Emerging Research and Future Directions

The trajectory of Flurbiprofen research reflects a broader trend in pharmacology: moving beyond established mechanisms to explore new applications and develop safer delivery systems.

• Novel Formulations for Risk Mitigation: A key area of ongoing investigation is the development of novel formulations designed to improve the drug's safety profile. Research into transdermal delivery systems, such as the Esflurbiprofen Hydrogel Patch (EFHP), aims to provide effective, localized analgesia for conditions like chronic low back pain while significantly reducing the systemic drug exposure and associated GI and cardiovascular risks seen with oral tablets.[83] This represents a logical extension of the risk-mitigation strategy already proven successful with the ophthalmic and oromucosal formulations.
• Prodrugs and Chemical Derivatives: To address the inherent GI toxicity of the parent molecule, scientists are actively synthesizing novel Flurbiprofen derivatives and mutual prodrugs. One promising strategy involves temporarily masking the free carboxylic acid group—the moiety largely responsible for direct gastric irritation—through esterification with natural antioxidants.[84] These prodrugs are designed to be inactive in the stomach and are only hydrolyzed to release the active Flurbiprofen after absorption, potentially reducing local GI damage.
• Exploration of New Therapeutic Targets: Perhaps the most exciting frontier for Flurbiprofen is the investigation of its non-COX-mediated effects for entirely new therapeutic indications. The discovery that the R-enantiomer can modulate the activity of γ-secretase, leading to a selective reduction in the production of the neurotoxic amyloid-beta 42 peptide (Aβ42), has positioned R-flurbiprofen as a potential disease-modifying agent for Alzheimer's disease.[23] Because R-flurbiprofen lacks significant COX-inhibiting activity, it could theoretically be developed as a targeted therapy for this neurodegenerative disease without carrying the classic NSAID-related side effects.

8.3. Final Assessment

In summary, Flurbiprofen is a mature therapeutic agent that embodies both the power and the peril of the non-selective NSAID class. Its history reflects the evolution of anti-inflammatory therapy: from an initial focus on achieving potent efficacy to a more sophisticated, modern understanding of the critical need for risk management. This management is now being achieved through careful patient stratification, the integration of pharmacogenomic considerations like CYP2C9 status, and the development of innovative drug delivery strategies. The future of Flurbiprofen and similar molecules may lie less in their traditional role as systemic anti-inflammatory agents and more in the development of enantiopure preparations, targeted local formulations, and novel applications that leverage their complex biological activities far beyond simple cyclooxygenase inhibition.

Works cited

1. Flurbiprofen: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/drugs/DB00712
2. Flurbiprofen - Wikipedia, accessed August 19, 2025, https://en.wikipedia.org/wiki/Flurbiprofen
3. KEGG DRUG: Flurbiprofen - (www.genome.jp)., accessed August 19, 2025, https://www.genome.jp/dbget-bin/www_bget?drug:D00330
4. Flurbiprofen | C15H13FO2 | CID 3394 - PubChem, accessed August 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Flurbiprofen
5. Flurbiprofen - LiverTox - NCBI Bookshelf, accessed August 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548121/
6. flurbiprofen | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 19, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194
7. Flurbiprofen (International database) - Drugs.com, accessed August 19, 2025, https://www.drugs.com/international/flurbiprofen.html
8. Flurbiprofen - brand name list from Drugs.com, accessed August 19, 2025, https://www.drugs.com/ingredient/flurbiprofen.html
9. Ansaid - accessdata.fda.gov, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018766s015lbl.pdf
10. Flurbiprofen 5104-49-4 | Tokyo Chemical Industry Co., Ltd.(APAC), accessed August 19, 2025, https://www.tcichemicals.com/OP/en/p/F0371
11. Flurbiprofen vs Ibuprofen | Power - Clinical Trials, accessed August 19, 2025, https://www.withpower.com/guides/flurbiprofen-vs-ibuprofen
12. Flurbiprofen Binding Mechanism Explained - Ontosight | AI, accessed August 19, 2025, https://ontosight.ai/glossary/term/flurbiprofen-binding-mechanism-explained--67a2bea8c445bf945af55d97
13. European experience with flurbiprofen. A new analgesic/anti-inflammatory agent - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/3963022/
14. R-Flurbiprofen Traps Prostaglandins within Cells by Inhibition of Multidrug Resistance-Associated Protein-4, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5297703/
15. What is the mechanism of Flurbiprofen Sodium? - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-flurbiprofen-sodium
16. What is the mechanism of Flurbiprofen? - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-flurbiprofen
17. Showing BioInteractions for Flurbiprofen (DB00712) | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/drugs/DB00712/biointeractions
18. Flurbiprofen Monograph for Professionals - Drugs.com, accessed August 19, 2025, https://www.drugs.com/monograph/flurbiprofen.html
19. Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition - PNAS, accessed August 19, 2025, https://www.pnas.org/doi/10.1073/pnas.0913377107
20. Flurbiprofen | CAS 5104-49-4 - Tocris Bioscience, accessed August 19, 2025, https://www.tocris.com/products/flurbiprofen_1769
21. (±)-Flurbiprofen (Ansaid, CAS Number: 5104-49-4) | Cayman Chemical, accessed August 19, 2025, https://www.caymanchem.com/product/70250/(%C2%B1)-flurbiprofen
22. Flurbiprofen Pathway, Pharmacokinetics - PharmGKB, accessed August 19, 2025, https://www.clinpgx.org/pathway/PA166245301
23. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo - JCI, accessed August 19, 2025, https://www.jci.org/articles/view/18162
24. Ansaid flurbiprofen tablets, USP - accessdata.fda.gov, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018766s013lbl.pdf
25. Flurbiprofen - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed August 19, 2025, https://www.ncbi.nlm.nih.gov/sites/books/NBK500754/
26. Flurbiprofen metabolism. A. Simplified metabolism of flurbiprofen in... | Download Scientific Diagram - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/figure/Flurbiprofen-metabolism-A-Simplified-metabolism-of-flurbiprofen-in-humans-B-FLB-R_fig2_273951857
27. Drugs@FDA: Drug Product FLURBIPROFEN SODIUM (flurbiprofen sodium), NDA019404, Rebel Distributors Corp - ClinPGx, accessed August 19, 2025, https://www.clinpgx.org/literature/15102022
28. Flurbiprofen Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 19, 2025, https://www.drugs.com/dosage/flurbiprofen.html
29. warning: risk of serious cardiovascular and gastrointestinal events - Pfizer, accessed August 19, 2025, https://labeling.pfizer.com/showlabeling.aspx?id=955
30. Flurbiprofen - FPnotebook, accessed August 19, 2025, https://fpnotebook.com/Pharm/Analgesic/Flrbprfn.htm
31. Flurbiprofen (oral route) - Side effects & dosage - Mayo Clinic, accessed August 19, 2025, https://www.mayoclinic.org/drugs-supplements/flurbiprofen-oral-route/description/drg-20069793
32. Reference ID: 3928083 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018766s020lbl.pdf
33. Flurbiprofen: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 19, 2025, https://www.rxlist.com/flurbiprofen/generic-drug.htm
34. Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/391529/
35. Flurbiprofen in the symptomatic management of rheumatoid arthritis: A valuable alternative, accessed August 19, 2025, https://www.researchgate.net/publication/6241693_Flurbiprofen_in_the_symptomatic_management_of_rheumatoid_arthritis_A_valuable_alternative
36. Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative, accessed August 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK73709/
37. Single dose oral flurbiprofen for acute postoperative pain in adults - PMC - PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4164829/
38. Flurbiprofen (ophthalmic route) - Side effects & dosage - Mayo Clinic, accessed August 19, 2025, https://www.mayoclinic.org/drugs-supplements/flurbiprofen-ophthalmic-route/description/drg-20075693
39. Flurbiprofen Ophthalmic | Saint Luke's Health System, accessed August 19, 2025, https://www.saintlukeskc.org/health-library/flurbiprofen-ophthalmic
40. Flurbiprofen eye solution - Cleveland Clinic, accessed August 19, 2025, https://my.clevelandclinic.org/health/drugs/20019-flurbiprofen-eye-solution
41. Flurbiprofen sodium: Uses, Side Effects, Dosage & Reviews - GoodRx, accessed August 19, 2025, https://www.goodrx.com/flurbiprofen-sodium/what-is
42. Flurbiprofen 0.03% Ophthalmic Solution | Shop myVCA - VCA Animal Hospitals, accessed August 19, 2025, https://vcahospitals.com/shop/product/flurbiprofen-ophthalmic-solution
43. Flurbiprofen Lozenges (Brand Name Strepsils Maxpro): Uses, Dosage, and Precautions, accessed August 19, 2025, https://www.vinmec.com/eng/blog/flurbiprofen-lozenges-brand-name-strepsils-maxpro-uses-usage-and-precautions-for-use-en
44. Lozenges Flurbiprofen - Geiserpharma, accessed August 19, 2025, https://geiserpharma.com/portfolio-item/lozenges-flurbiprofen/
45. Flurbiprofen lozenges - Patient.info, accessed August 19, 2025, https://patient.info/medicine/flurbiprofen-lozenges-strefen
46. A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions - Frontiers, accessed August 19, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1107185/full
47. Strefen Honey and Lemon, accessed August 19, 2025, https://www.medicines.org.uk/emc/files/pil.6514.pdf
48. Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial, accessed August 19, 2025, https://bjgp.org/content/63/607/e149
49. Efficacy of flurbiprofen 8.75 mg lozenge in patients with a swollen and inflamed sore throat - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/27146963/
50. Flurbiprofen 8.75 mg lozenges for treating sore throat symptoms: a randomized, double-blind, placebo-controlled study - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/27734772/
51. Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: a randomized, non-inferiority trial in the Russian Federation - PMC - PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5505534/
52. (PDF) Evidence of the Efficacy of Flurbiprofen 8.75 mg Lozenges for Patients Receiving Antibiotics for Laboratory-Confirmed Streptococcal Pharyngitis - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/publication/353264211_Evidence_of_the_Efficacy_of_Flurbiprofen_875_mg_Lozenges_for_Patients_Receiving_Antibiotics_for_Laboratory-Confirmed_Streptococcal_Pharyngitis
53. Ansaid, Fluprofen (flurbiprofen) dosing, indications, interactions, adverse effects, and more, accessed August 19, 2025, https://reference.medscape.com/drug/ansaid-flurbiprofen-343288
54. Flurbiprofen - Arthritis Foundation, accessed August 19, 2025, https://www.arthritis.org/drug-guide/nsaids/flurbiprofen
55. FlurbiPro Dosage Guide - Drugs.com, accessed August 19, 2025, https://www.drugs.com/dosage/flurbipro.html
56. Comparison of two dosing schedules of flurbiprofen for patients with rheumatoid arthritis. Twice-daily versus four-times-a-day schedules - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/3515921/
57. Flurbiprofen: Side Effects, Dosage, Uses, and More - Healthline, accessed August 19, 2025, https://www.healthline.com/health/drugs/flurbiprofen-oral-tablet
58. Flurbiprofen, Ophthalmic, accessed August 19, 2025, https://www.iopeyes.com/wp-content/uploads/2019/06/Flurbiprofen-Ophthalmic-drops-2019.pdf
59. Amici Pharma FLURBIPROFEN 0.03 % OPHTHALMIC SOLUTION (Bottle, 2.5 Milliliter), accessed August 19, 2025, https://pharmacy.amazon.com/Flurbiprofen-Generic-for-Ocufen-Ophthalmic-Solution/dp/B08DSGHFZ5
60. Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% (Sterile) - DailyMed, accessed August 19, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=11db354f-caf9-4567-811e-6c9beb1330c7
61. Flurbiprofen ophthalmic dosing, indications, interactions, adverse effects, and more, accessed August 19, 2025, https://reference.medscape.com/drug/flurbiprofen-ophthalmic-343642
62. Contains Flurbiprofen 8.75 mg per lozenge Indication: Symptomatic relief of sore throat Dosage and administration - myCME, accessed August 19, 2025, https://media.mycme.com/documents/55/strefen_pi_13713.pdf
63. Strefen Sore Throat Lozenges x 16 | Medicines | Buy Online at PeakPharmacy, accessed August 19, 2025, https://www.peakpharmacy.co.uk/medications/strefen-sore-throat-lozenges-x-16
64. Flurbiprofen (Oral) Advanced Patient Information - Drugs.com, accessed August 19, 2025, https://www.drugs.com/cons/flurbiprofen-oral.html
65. Flurbiprofen Tablets: Package Insert / Prescribing Info - Drugs.com, accessed August 19, 2025, https://www.drugs.com/pro/flurbiprofen-tablets.html
66. Ansaid (Flurbiprofen): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 19, 2025, https://www.rxlist.com/ansaid-drug.htm
67. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes, accessed August 19, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory
68. Flurbiprofen: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 19, 2025, https://www.webmd.com/drugs/2/drug-13459/flurbiprofen-oral/details
69. ANSAID® - Pfizer, accessed August 19, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=15210
70. flurbiprofen tablet, film coated STAT RX USA LLC - DailyMed, accessed August 19, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9ce60fd6-b58b-4b7c-835d-305107552f44&type=display
71. Flurbiprofen Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 19, 2025, https://www.drugs.com/sfx/flurbiprofen-side-effects.html
72. Flurbiprofen Interactions Checker - Drugs.com, accessed August 19, 2025, https://www.drugs.com/drug-interactions/flurbiprofen.html
73. Flurbiprofen - Oral - MyHealth Alberta, accessed August 19, 2025, https://myhealth.alberta.ca/Health/medications/pages/conditions.aspx?hwid=fdb0462
74. What is Flurbiprofen used for? - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/article/what-is-flurbiprofen-used-for
75. Flurbiprofen Uses, Side Effects & Warnings - Drugs.com, accessed August 19, 2025, https://www.drugs.com/mtm/flurbiprofen.html
76. Flurbiprofen and Alcohol/Food Interactions - Drugs.com, accessed August 19, 2025, https://www.drugs.com/food-interactions/flurbiprofen.html
77. Flurbiprofen Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed August 19, 2025, https://www.wellrx.com/flurbiprofen/lifestyle-interactions/
78. COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | FDA, accessed August 19, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cox-2-selective-includes-bextra-celebrex-and-vioxx-and-non-selective-non-steroidal-anti-inflammatory
79. Definition of flurbiprofen - NCI Drug Dictionary, accessed August 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/flurbiprofen
80. Flurbiprofen Sodium Medicare Coverage and Co-Pay Details - GoodRx, accessed August 19, 2025, https://www.goodrx.com/flurbiprofen-sodium/medicare-coverage
81. dl-Flurbiprofen - COX Inhibitor - MedchemExpress.com, accessed August 19, 2025, https://www.medchemexpress.com/Flurbiprofen.html
82. Flurbiprofen API Suppliers - Find All GMP Manufacturers - Pharmaoffer.com, accessed August 19, 2025, https://pharmaoffer.com/api-excipient-supplier/nsaids/flurbiprofen
83. Study Details | S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet | ClinicalTrials.gov, accessed August 19, 2025, https://www.clinicaltrials.gov/study/NCT04505787?term=FLURBIPROFEN&rank=8
84. Synthesis of flurbiprofen–antioxidant mutual prodrugs. - ResearchGate, accessed August 19, 2025, https://www.researchgate.net/figure/Synthesis-of-flurbiprofen-antioxidant-mutual-prodrugs_fig1_305697049
85. Novel Flurbiprofen Derivatives as Antioxidant and Anti-Inflammatory Agents: Synthesis, In Silico, and In Vitro Biological Evaluation - MDPI, accessed August 19, 2025, https://www.mdpi.com/1420-3049/29/2/385